Organigram (OGI) Given New C$7.00 Price Target at Eight Capital

Organigram (CVE:OGI) had its target price hoisted by Eight Capital from C$4.50 to C$7.00 in a research report issued on Monday. Eight Capital’s price objective suggests a potential upside of 61.66% from the stock’s current price.

Separately, Canaccord Genuity set a C$5.50 target price on Organigram in a research report on Wednesday, March 7th.

Shares of Organigram (OGI) traded up C$0.02 during mid-day trading on Monday, reaching C$4.33. The company had a trading volume of 342,290 shares, compared to its average volume of 2,237,305. The firm has a market capitalization of $526.95, a price-to-earnings ratio of -39.27 and a beta of 8.35. Organigram has a 1 year low of C$2.00 and a 1 year high of C$5.68.

Organigram (CVE:OGI) last announced its quarterly earnings data on Monday, January 29th. The company reported C($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of C($0.01). The firm had revenue of C$2.69 million during the quarter, compared to analyst estimates of C$2.86 million.

TRADEMARK VIOLATION WARNING: “Organigram (OGI) Given New C$7.00 Price Target at Eight Capital” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at

About Organigram

OrganiGram Holdings Inc, through its subsidiary, Organigram Inc, produces and sells medical marijuana in Canada. The company was founded in 2013 and is based in Moncton, Canada.

Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with's FREE daily email newsletter.

Leave a Reply